Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Sep 24;16(1):161.
doi: 10.1186/s12916-018-1150-3.

Inflammation and micronutrient biomarkers predict clinical HIV treatment failure and incident active TB in HIV-infected adults: a case-control study

Rupak Shivakoti  1   2 , Nikhil Gupte  3 , Srikanth Tripathy  4   5 , Selvamuthu Poongulali  6 , Cecilia Kanyama  7 , Sima Berendes  8   9 , Sandra W Cardoso  10 , Breno R Santos  11 , Alberto La Rosa  12 , Noluthando Mwelase  13 , Sandy Pillay  14 , Wadzanai Samaneka  15 , Cynthia Riviere  16 , Patcharaphan Sugandhavesa  17 , Robert C Bollinger  3   18 , Ashwin Balagopal  3 , Richard D Semba  19 , Parul Christian  18   20 , Thomas B Campbell  21 , Amita Gupta  3 ; NWCS 319 and PEARLS Study Team
Affiliations
Randomized Controlled Trial

Inflammation and micronutrient biomarkers predict clinical HIV treatment failure and incident active TB in HIV-infected adults: a case-control study

Rupak Shivakoti et al. BMC Med. .

Abstract

Background: Various individual biomarkers of inflammation and micronutrient status, often correlated with each other, are associated with adverse treatment outcomes in human immunodeficiency virus (HIV)-infected adults. The objective of this study was to conduct exploratory factor analysis (EFA) on multiple inflammation and micronutrient biomarkers to identify biomarker groupings (factors) and determine their association with HIV clinical treatment failure (CTF) and incident active tuberculosis (TB).

Methods: Within a multicountry randomized trial of antiretroviral therapy (ART) efficacy (PEARLS) among HIV-infected adults, we nested a case-control study (n = 290; 124 cases, 166 controls) to identify underlying factors, based on EFA of 23 baseline (pre-ART) biomarkers of inflammation and micronutrient status. The EFA biomarker groupings results were used in Cox proportional hazards models to study the association with CTF (primary analysis where cases were incident World Health Organization stage 3, 4 or death by 96 weeks of ART) or incident active TB (secondary analysis).

Results: In the primary analysis, based on eigenvalues> 1 in the EFA, three factors were extracted: (1) carotenoids), (2) other nutrients, and (3) inflammation. In multivariable-adjusted models, there was an increased hazard of CTF (adjusted hazard ratio (aHR) 1.47, 95% confidence interval (CI)1.17-1.84) per unit increase of inflammation factor score. In the secondary incident active TB case-control analysis, higher scores of the high carotenoids and low interleukin-18 factor was protective against incident active TB (aHR 0.48, 95% CI 0.26-0.87).

Conclusion: Factors identified through EFA were associated with adverse outcomes in HIV-infected individuals. Strategies focused on reducing adverse HIV outcomes through therapeutic interventions that target the underlying factor (e.g., inflammation) rather than focusing on an individual observed biomarker might be more effective and warrant further investigation.

Keywords: Antiretroviral therapy; Exploratory factor analysis; HIV; IL-18; Inflammation; Tuberculosis.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Ethics committees and institutional review boards from Johns Hopkins University (JHU) and participating site institutions approved this study. This study utilized bio-banked samples from individuals who had originally consented to the use of samples for future research.

Consent for publication

This manuscript only discusses analyses from de-identified data.

Competing interests

Thomas B. Campbell is an advisory board member for Gilead Sciences and Theratechnologies, Inc. Amita Gupta and Rupak Shivakoti have received grant funding from Gilead Foundation. All other authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

    1. Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, Bohjanen PR, Novak RM, Neaton JD, Sereti I. Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. J Infect Dis. 2011;203(11):1637–1646. doi: 10.1093/infdis/jir134. - DOI - PMC - PubMed
    1. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009;17(4):118–123. - PubMed
    1. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013;39(4):633–645. doi: 10.1016/j.immuni.2013.10.001. - DOI - PMC - PubMed
    1. Ledwaba L, Tavel JA, Khabo P, Maja P, Qin J, Sangweni P, Liu X, Follmann D, Metcalf JA, Orsega S, et al. Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One. 2012;7(3):e24243. doi: 10.1371/journal.pone.0024243. - DOI - PMC - PubMed
    1. Balagopal A, Gupte N, Shivakoti R, Cox AL, Yang WT, Berendes S, Mwelase N, Kanyama C, Pillay S, Samaneka W, et al. Continued elevation of interleukin-18 and interferon-gamma after initiation of antiretroviral therapy and clinical failure in a diverse multicountry human immunodeficiency virus cohort. Open Forum Infect Dis. 2016;3(3):ofw118. doi: 10.1093/ofid/ofw118. - DOI - PMC - PubMed

Publication types

MeSH terms